Literature DB >> 3477902

Prognostic value of serum alkaline phosphatase in osteosarcoma.

G Bacci1, P Picci, M Orlandi, M Avella, M Manfrini, G Pignatti, D Dallari, R Manduchi.   

Abstract

In 163 patients with osteosarcoma of the extremities treated with adjuvant chemotherapy, serum alkaline phosphatase (SAP) levels were evaluated before treatment and successively closely monitored in an attempt to determine whether serum levels of this enzyme had clinical value in predicting the course of the disease. Of 121 patients with elevated preoperative SAP levels, 78 (64%) recurred. Of 42 patients with normal preoperative SAP levels, only 8 (19%) recurred (P less than 0.00001). Of the 140 patients locally treated with amputation, SAP returned to normal values in 77 patients; 46 of these (59%) relapsed. Of the 21 patients whose SAP remained elevated after amputation, all but 2 relapsed (90%). Among 119 patients with normal postoperative values of SAP, at the time of relapse SAP resulted elevated in 22 of 41 patients (53%). These data confirm that in osteosarcoma, preoperative SAP levels have a definite value in establishing the prognosis and that posttreatment follow-up examination should include SAP determination, since persistent elevated or increasing values herald the appearance of a recurrence.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3477902     DOI: 10.1177/030089168707300402

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  2 in total

1.  Clinical significance of circulating miR-25-3p as a novel diagnostic and prognostic biomarker in osteosarcoma.

Authors:  Tomohiro Fujiwara; Koji Uotani; Aki Yoshida; Takuya Morita; Yutaka Nezu; Eisuke Kobayashi; Akihiko Yoshida; Takenori Uehara; Toshinori Omori; Kazuhisa Sugiu; Tadashi Komatsubara; Ken Takeda; Toshiyuki Kunisada; Machiko Kawamura; Akira Kawai; Takahiro Ochiya; Toshifumi Ozaki
Journal:  Oncotarget       Date:  2017-05-16

2.  Secondary osteosarcoma arising after treatment for childhood hematologic malignancies.

Authors:  Atsushi Okada; Masahito Hatori; Masami Hosaka; Munenori Watanuki; Eiji Itoi
Journal:  Ups J Med Sci       Date:  2009       Impact factor: 2.384

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.